BillionToOne, Inc. Class A (BLLN) has received a new Buy rating, initiated by J.P. Morgan analyst, Casey Woodring.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Casey Woodring’s rating is based on BillionToOne’s innovative technology and promising growth prospects. The company has developed a proprietary single molecule next-generation sequencing platform that enhances the accuracy of prenatal and oncology testing. This technological edge has allowed BillionToOne to capture significant market share in the prenatal segment and is expected to drive growth in the oncology segment, particularly with the anticipated launch of a new tissue-free MRD test in 2026.
Furthermore, BillionToOne’s financial projections are strong, with a forecasted revenue growth CAGR of 29% from 2025 to 2030 and an expected operating margin of 9% by 2028. Despite the stock’s substantial gain since its IPO, the company’s strategic expansion of its salesforce and its ability to efficiently scale operations are expected to sustain its growth trajectory. These factors, combined with a favorable market environment and BillionToOne’s competitive positioning, underpin Woodring’s Buy rating and the $150 price target for December 2026.
Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BLLN in relation to earlier this year.